Please ensure Javascript is enabled for purposes of website accessibility

Gilead Aims to Get Its Potential COVID-19 Drug to as Many Patients as Possible

By Cory Renauer – May 1, 2020 at 2:07PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Once the FDA approves remdesivir, the drugmaker will donate the first 1.5 million doses.

On Friday, Gilead Sciences (GILD -0.76%) promised to make its experimental coronavirus treatment, remdesivir, accessible to as many people as possible. Recently released clinical trial results suggest the antiviral can significantly reduce the time of recovery for hospitalized COVID-19 patients.

The Food and Drug Administration is expected to issue an emergency-use authorization for remdesivir in record time. A EUA is not the same as a formal approval for the drug as a treatment, but it will make it easier for providers to administer the antiviral to more patients. 

Hand holding a vial of COVID-19 blood.

Image source: Getty Images.

In a government-sponsored study, a majority of patients treated with remdesivir recovered after 11 days compared to 15 days among those given a placebo. Based on that, the wider use of remdesivir could help hospitals stretch their limited intensive-care resources significantly further.

Treading carefully

While a EUA to treat hospitalized COVID-19 patients seems likely for remdesivir, the FDA will probably wait for results from ongoing clinical trials sponsored by Gilead Sciences before considering full approval. Gilead Sciences is running a study meant to enroll around 1,600 patients with moderate cases of COVID-19  and measure their progress after 11 days of treatment with either remdesivir or standard care.

Gilead's also enrolling an expected 6,000 patients with severe cases of COVID-19 into a study comparing remdesivir to standard care. This one will take a bit longer because investigators aren't taking measurements until day 14, but results that confirm data from the NIH trial would be worth the wait.

In the meantime, Gilead is cranking up production of remdesivir and intends to donate the first 1.5 million doses that roll off the line.

Cory Renauer owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences Stock Quote
Gilead Sciences
GILD
$64.95 (-0.76%) $0.50

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.